XML 85 R65.htm IDEA: XBRL DOCUMENT v3.25.4
License and Acquisition Agreements - Biogen Asset Purchase Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Aug. 31, 2022
Sep. 30, 2016
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
License and Acquisition Agreements          
Research and development     $ 96,853 $ 111,623 $ 76,097
Maximum          
License and Acquisition Agreements          
Royalty rate increase (percentage) 1.00%        
Asset purchase agreement          
License and Acquisition Agreements          
Upfront payment for exchange of rights   $ 11,500      
Technology transfer payment   500      
Asset purchase agreement | Biogen          
License and Acquisition Agreements          
Remaining milestone payments to be paid upon clinical and regulatory milestone achievement     165,000    
One-time payment of upfront sublicense fee on retained contracts   $ 150      
Notice period to terminate the agreement   90 days      
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured   90 days      
Notice period to terminate the agreement under payment-related breaches   30 days      
Research and development     44 $ 144 $ 94
Asset purchase agreement | Biogen | Maximum          
License and Acquisition Agreements          
Milestone payment to be paid upon clinical and regulatory milestone achievement     179,000    
Milestone payment to be paid upon net sales milestone achievement     $ 150,000    
Maximum aggregate obligation to pay insignificant annual maintenance fees as well as clinical and regulatory milestone payments   $ 1,575